Host: Matt Birnholz, MD

Guest: Jason M. Leider, MD, PhD

To help physicians prepare for those times when they diagnose HIV-1 in treatment-naive patients, Dr. Leider shares his perspective on treating HIV-1 in patients that may have refused care at time of initial diagnosis, have not had resistance testing performed at time of diagnosis, or are unable to locate their medical records. Dr. Leider will also cover the background of the recent trial AMBER in HIV-1 treatment-naïve patients.

ARV - antiretroviral drugs

Indication and Important Safety Information

INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults:

• who have no prior antiretroviral treatment history or
• who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of ...